SCT signs joint-venture agreement with Reneu, Nexgen
As part of the agreement, SCT and NexGen will license their respective technologies to ReNeu under world-wide, royalty-free licenses for the use of NexGen’s FDA-cleared EViTAR line of
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Under the licenses, Cedars-Sinai Medical Center can use Neuralstem’s intellectual property surrounding of spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents. Cedars-Sinai Medical Center